Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3408847 | 0.80 | EGLN1 (0.62) | EGLN1LMNAADORA3ADORA2AADORA1 | |
| SCHEMBL1819465 | 0.79 | LMNA (0.49) | EGLN1LMNAADORA3ADORA2AADORA1 | |
| SCHEMBL3435155 | 0.78 | EGLN1 (0.63) | EGLN1LMNAMAPK1KDM4EALDH1A1 | |
| SCHEMBL3405250 | 0.78 | EGLN1 (0.63) | EGLN1LMNAMAPK1KDM4EALDH1A1 | |
| SCHEMBL4535795 | 0.78 | EGLN1 (0.63) | EGLN1LMNAMAPK1KDM4EALDH1A1 | |
| SCHEMBL3430124 | 0.78 | EGLN1 (0.49) | EGLN1LMNAMAPK1ALDH1A1KCNH2 | |
| SCHEMBL2567010 | 0.76 | ALOX15 (0.44) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL3427861 | 0.76 | EGLN1 (0.48) | EGLN1LMNAMAPK1ALDH1A1HPGD | |
| SCHEMBL4534009 | 0.76 | EGLN1 (0.50) | EGLN1MAPK1KCNH2 | |
| SCHEMBL4530923 | 0.76 | EGLN1 (0.58) | EGLN1LMNAADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | claimed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | claimed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | claimed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2560655-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | EGLN1 7/4885ESR1 2076/4885ESR2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.